In the BioHarmony Drug Report Database

"Preview" Icon

Vemurafenib

Zelboraf (vemurafenib) is a small molecule pharmaceutical. Vemurafenib was first approved as Zelboraf on 2011-08-17. It is used to treat melanoma in the USA. It has been approved in Europe to treat melanoma. The pharmaceutical is active against serine/threonine-protein kinase B-raf. In addition, it is known to target RAF proto-oncogene serine/threonine-protein kinase. Zelboraf’s patents are valid until 2032-06-06 (FDA).

 

Trade Name

 

Zelboraf
 

Common Name

 

vemurafenib
 

ChEMBL ID

 

CHEMBL1229517
 

Indication

 

melanoma
 

Drug Class

 

Raf kinase inhibitors

Image (chem structure or protein)

Vemurafenib structure rendering